Bicalutamide is adumbrated for the analysis of date D2 metastatic prostate blight in aggregate with a luteinizing hormone-releasing hormone alternation or as a monotherapy. It has aswell been acclimated in analytic trials for ovarian cancer. It has aswell been acclimated in aggregate with castration.
Most avant-garde prostate blight patients eventually become aggressive to antiandrogen including bicalutamide therapy.
Bicalutamide has been activated with acceptable after-effects for analysis of androgen receptor absolute ER-/PR- locally avant-garde and metastatic breast blight in a appearance II abstraction and is acclimated off-label for this indication. The newer anitandrogen enzalutamide may aswell authority some affiance for this blazon of tumours but has been so far activated alone in vitro.